China’s central bank bought more gold in February, extending its streak of purchasing to 16 months, as bullion climbs amid escalating Middle East tensions. Gold held by the People’s Bank of China rose by 30,000 troy ounces last month to 74.22 million fine troy ounces, according to data released on Saturday. The purchase extends the latest round of accumulation that began in November 2024. Despite ...
China’s central bank bought more gold in February, extending its streak of purchasing to 16 months, as bullion climbs amid escalating Middle East tensions. Gold held by the People’s Bank of China rose by 30,000 troy ounces last month to 74.22 million fine troy ounces, according to data released on Saturday. The purchase extends the latest round of accumulation that began in November 2024. Despite recent declines, gold has gained over the past few weeks, clawing its way back above $5,000 an ounce. Investors were seeking safer assets after the US and Israel attacked Iran, intensifying geopolitical risks in the Middle East. Global central banks’ gold purchases slowed at the start of the year, as heightened volatility weighed on appetite, according to a note from the producer-funded World Gold Council this week. Net buying, led by Central and East Asian countries, totaled five tons in January, compared with a 12-month average of 27 tons. “Volatile gold prices and the holiday season may have given some central banks pause,” Marissa Salim, an analyst from WGC, wrote in the note. “Though geopolitical tensions, which have shown little sign of abating, are likely to keep accumulation going through 2026 and beyond.” Some countries have also sold gold recently, but buying still outweighs selloffs. The head of Poland’s central bank — the world’s biggest reported buyer of bullion — laid out a proposal to sell gold reserves to finance defense spending, whereas both Russia and Venezuela’s central banks have sold gold in recent months.
Key Points GOODNOW Investment Group, LLC bought 131,723 shares; estimated transaction value of $5.39 million (based on average closing price October–December 2025) Quarter-end position value increased by $16.17 million, reflecting both trading and price changes Transaction represents 0.5% of 13F reportable AUM New stake totals 1,377,881 shares, valued at $61.98 million Position accounts for 5.78% ...
Key Points GOODNOW Investment Group, LLC bought 131,723 shares; estimated transaction value of $5.39 million (based on average closing price October–December 2025) Quarter-end position value increased by $16.17 million, reflecting both trading and price changes Transaction represents 0.5% of 13F reportable AUM New stake totals 1,377,881 shares, valued at $61.98 million Position accounts for 5.78% of fund AUM, which places it outside the fund's top five holdings 10 stocks we like better than Instacart › What happened According to a recent SEC filing, GOODNOW Investment Group, LLC added 131,723 shares of Maplebear (NASDAQ:CART) during the fourth quarter of 2025. The value of the position at quarter-end increased by $16.17 million, which includes both the new shares acquired and changes in the underlying stock price. What else to know The fund raised its investment in CART, which now represents 5.78% of 13F AUM Top holdings after the filing: NYSE:CVNA: $299.67 million (28.0% of AUM) NYSE:GDDY: $92.04 million (8.6% of AUM) NASDAQ:EXPE: $74.53 million (7.0% of AUM) NYSE:W: $63.55 million (5.9% of AUM) NYSE:APTV: $57.25 million (5.3% of AUM) As of February 16, 2026, shares were priced at $36.30, down 27.4% over the past year and lagging the S&P 500 by 39.18 percentage points Company overview Metric Value Price (as of market close 2/13/26) $36.30 Market Capitalization $9.53 billion Revenue (TTM) $3.63 billion Net Income (TTM) $514.00 million Company snapshot Maplebear, doing business as Instacart, provides online grocery shopping services to households in North America. Maplebear provides online grocery shopping and delivery services, connecting consumers with personal shoppers for food, alcohol, consumer health, pet care, and ready-made meals. The company leverages a two-sided marketplace to connect consumers with personal shoppers, enabling rapid fulfillment of a wide range of household needs. The company operates through a mobile application and website, facilitating ra...
Trump administration's embattled FDA vaccine chief is leaving for the second time toggle caption AP/U.S. Food and Drug Administration WASHINGTON — The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions involving the review of vaccinations and specialty drug...
Trump administration's embattled FDA vaccine chief is leaving for the second time toggle caption AP/U.S. Food and Drug Administration WASHINGTON — The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions involving the review of vaccinations and specialty drugs for rare diseases. FDA Commissioner Marty Makary announced the news to FDA staff in an email late Friday, saying Prasad would depart at the end of April. Makary said Prasad would return to his academic job at the University of California, San Francisco. Sponsor Message In July, Prasad was briefly forced from his job after running afoul of biotech executives, patient groups and conservative allies of President Donald Trump. He was reinstated less than two weeks later with the backing of Health Secretary Robert F. Kennedy Jr. and Makary. Prasad's latest ouster follows a string of high-profile controversies involving the FDA's review of vaccines, gene therapies and biotech drugs in which companies have criticized the agency for reversing itself, in some cases calling for new trials of products previously greenlighted by regulators. In the last month, Prasad has come under fire from pharmaceutical executives, investors, members of Congress and other critics for multiple decisions at the agency. First, Prasad initially refused to allow the FDA to review a highly anticipated flu vaccine from drugmaker Moderna made with mRNA technology. The rejection of the application, highly unusual for the FDA, prompted Moderna to go public with Prasad's decision and vow to formally challenge it. A week after the rejection became public, the FDA reversed course and said it would accept the shot for review after all, pending an additional study from Moderna. Then, in the past week, the FDA engaged in a highly unusual public fight with a small drug company developing an experimental treatment f...
Chinese Vice-Premier Ding Xuexiang has urged Hong Kong’s legislature to deliver more “practical outcomes” that align with the city’s actual conditions and meet Beijing’s expectations under the executive-led governance system. Emphasising the importance of the executive-led system for the second day in a row, the state leader reiterated on Saturday that its implementation was not solely the respons...
Chinese Vice-Premier Ding Xuexiang has urged Hong Kong’s legislature to deliver more “practical outcomes” that align with the city’s actual conditions and meet Beijing’s expectations under the executive-led governance system. Emphasising the importance of the executive-led system for the second day in a row, the state leader reiterated on Saturday that its implementation was not solely the responsibility of the city leader or the government, as he outlined his expectations for the Legislative Council. Ding, head of the Central Leading Group on Hong Kong and Macau Affairs, cited that President Xi Jinping had earlier set out new requirements for the city’s governance in response to the “new circumstances” and stressed that implementing the executive-led system was a shared responsibility of the legislature, judiciary and all sectors of society. Legco president Starry Lee has highlighted the legislature’s efforts to support the national 15th five-year plan. Photo: Eugene Lee “After this topic has been raised, all sectors must strengthen their research, exploration and practice, continuously summarising experiences,” Ding told the city’s deputies to the national legislature in a meeting during the “two sessions”. Advertisement “In particular, the Legco has tremendous scope to contribute under the executive-led system. There is vast room for practice, exploration and theoretical research. “I hope that, during the eighth Legco term, the legislature under the leadership of Starry Lee Wai-king will explore and study this topic well, and produce more practical outcomes that fit Hong Kong’s actual situation and meet the requirements of the central government.” Advertisement The sixth-ranked Politburo Standing Committee member made his remarks in response to a speech by Starry Lee, the Legco president and the city’s sole representative on the National People’s Congress (NPC) Standing Committee.
Broadcom (AVGO) reported its Q1 earnings on March 4. The company’s report was strong, with revenue hitting 29% year-over-year growth to a record $19.3 billion. The stock closed 4.8% higher at $322.77 on the next day, according to Yahoo Finance. AI-heavy stock not crashing following the earnings ...
Broadcom (AVGO) reported its Q1 earnings on March 4. The company’s report was strong, with revenue hitting 29% year-over-year growth to a record $19.3 billion. The stock closed 4.8% higher at $322.77 on the next day, according to Yahoo Finance. AI-heavy stock not crashing following the earnings ...
If you compare the latest quarterly results from Walmart (WMT +0.45%) and BJ's Wholesale Club (BJ 1.69%), one contrast is impossible to ignore. In its fiscal fourth quarter, Walmart's operating income jumped 10.8% year over year, easily outpacing its 5.6% revenue growth. BJ's, meanwhile, saw its total revenue increase by the exact same 5.6% in its most recent quarter, but its operating income actu...
If you compare the latest quarterly results from Walmart (WMT +0.45%) and BJ's Wholesale Club (BJ 1.69%), one contrast is impossible to ignore. In its fiscal fourth quarter, Walmart's operating income jumped 10.8% year over year, easily outpacing its 5.6% revenue growth. BJ's, meanwhile, saw its total revenue increase by the exact same 5.6% in its most recent quarter, but its operating income actually slipped 0.2% year over year. But BJ's does have an edge on its much larger competitor in one crucial area: valuation. So, which stock is the better buy today: the better operator with a demanding valuation, or the cheaper warehouse club? Walmart: a shifting profit profile Beneath Walmart's 5.6% top-line growth in fiscal Q4 were several underlying drivers pointing to a fundamentally improving business. The defining metric was the company's surging global e-commerce sales, which rose 24% year over year and now account for a record 23% of total net sales. Backing up this digital strength, U.S. comparable sales (excluding fuel) rose 4.6%, driven by a 2.6% increase in transactions. This proves Walmart is still driving real traffic, not just leaning on higher prices. Even more importantly, the company's highest-margin revenue streams are growing the fastest. Walmart's global advertising business surged 37% year over year in the quarter, with its U.S. ad segment, Walmart Connect, rising 41%. Further, global membership fee revenue increased 15.1%. All of these underlying factors help explain why the company commands such a high valuation. Its business is transforming. Expand NASDAQ : WMT Walmart Today's Change ( 0.45 %) $ 0.55 Current Price $ 123.86 Key Data Points Market Cap $983B Day's Range $ 121.62 - $ 124.18 52wk Range $ 79.81 - $ 134.69 Volume 1.3M Avg Vol 31M Gross Margin 25.40 % Dividend Yield 0.76 % And then there is Sam's Club. Walmart's warehouse club segment posted 4% comparable sales growth excluding fuel and 23% e-commerce growth in the quarter. And management no...
Regencell Bioscience (RGC 2.52%) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means...
Regencell Bioscience (RGC 2.52%) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means it's researching drugs it believes may have promise, but it hasn't found anything yet. This is a high-risk area of the pharmaceutical sector that only the most aggressive investors should consider. If a bioscience company's research leads to a marketable product, its stock could take off. If it doesn't, the company could have trouble remaining a going concern. It is a bit of a moonshot type of investment. In order to justify buying a company like Regencell, you need to believe very strongly in the drug candidates that the company is researching. Most investors should stick to more established pharmaceutical companies that already have a portfolio of patented drugs. Regencell has spent 14 years examining "TCM" What's interesting about Regencell is that it has been operating since 2014 and still doesn't have a patented drug. Its focus is on traditional Chinese medicine, which the company usually just describes as TCM on its website. Expand NASDAQ : RGC Regencell Bioscience Today's Change ( -2.52 %) $ -0.61 Current Price $ 23.60 Key Data Points Market Cap $12B Day's Range $ 23.60 - $ 24.82 52wk Range $ 0.10 - $ 83.60 Volume 1.9K Avg Vol 457K The foreign company's annual report states the risks very clearly, summing the problem up in one sentence: We have no saleable products and have not generated any revenue from product sales. Unless you are deeply versed in TCM and have a strong belief that Regencell is on the verge of some breakthrough, you should probably avoid this stock. Why I would avoid Regencell (and what I would buy instead) I wouldn't touch Regencell with a 10-foo...
Key Points Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine. 10 stocks we like better than Regencell Bioscience › Regencell Bioscience (NASDAQ: RGC) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It start...
Key Points Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine. 10 stocks we like better than Regencell Bioscience › Regencell Bioscience (NASDAQ: RGC) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means it's researching drugs it believes may have promise, but it hasn't found anything yet. This is a high-risk area of the pharmaceutical sector that only the most aggressive investors should consider. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » If a bioscience company's research leads to a marketable product, its stock could take off. If it doesn't, the company could have trouble remaining a going concern. It is a bit of a moonshot type of investment. In order to justify buying a company like Regencell, you need to believe very strongly in the drug candidates that the company is researching. Most investors should stick to more established pharmaceutical companies that already have a portfolio of patented drugs. Regencell has spent 14 years examining "TCM" What's interesting about Regencell is that it has been operating since 2014 and still doesn't have a patented drug. Its focus is on traditional Chinese medicine, which the company usually just describes as TCM on its website. The foreign company's annual report states the risks very clearly, summing the problem up in one sentence: We have no saleable products and have not generated any revenue from product sales...